Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/18/2847520/0/en/OBI-Pharma-Announces-Poster-Presentations-at-the-AACR-2024-Annual-Meeting-for-OBI-992-and-GlycOBI-ADC-platform.html
https://www.prnewswire.com/news-releases/biosions-partner-obi-pharma-announces-fda-clearance-of-ind-application-for-a-phase-12-study-of-obi-992-trop2-adc-302028402.html
https://www.globenewswire.com//news-release/2024/01/03/2803085/0/en/OBI-Pharma-Announces-U-S-FDA-Clearance-of-IND-Application-for-a-Phase-1-2-Study-of-OBI-992.html
https://www.globenewswire.com/news-release/2023/06/02/2680964/0/en/OBI-Pharma-Announces-Executive-Leadership-Management-Change-Heidi-Wang-Ph-D-Appointed-as-Chief-Executive-Officer.html
https://www.globenewswire.com/news-release/2023/04/10/2643419/0/en/OBI-Pharma-Announces-Poster-Presentations-at-AACR-2023-Annual-Meeting-for-OBI-999-combination-synergy-with-checkpoint-inhibitor-as-well-as-Globo-H-targeted-CAR-T-cell-immunotherapy.html
https://www.globenewswire.com/news-release/2022/07/05/2474425/0/en/OBI-Pharma-Announces-Discontinuation-of-the-Phase-1-2-Study-of-its-Antibody-OBI-888-to-focus-on-other-priority-Cancer-programs.html
https://www.globenewswire.com/news-release/2022/05/17/2444610/0/en/OBI-Pharma-Announces-Poster-Presentations-at-the-2022-ASCO-Annual-Meeting-for-Adagloxad-Simolenin-OBI-999-OBI-3424-and-Exhibition-Booth.html
https://www.prnewswire.com/news-releases/obi-pharma-announces-poster-presentations-at-aacr-2022-annual-meeting-for-obi-3424-and-globo-h-science-301519671.html
https://www.prnewswire.com/news-releases/biosion-inc-licenses-bsi04702-an-anti-trop-2-mab-to-obi-pharma-inc-for-worldwide-development-and-commercialization-rights-as-an-antibody-drug-conjugate--and-other-derivative-products-301442963.html
https://www.prnewswire.com/news-releases/obi-pharma-announces-first-patient-enrolled-on-swog-cancer-research-networks-obi-3424-phase-12-study-targeting-akr1c3-in-t-all-and-t-lbl-301275694.html